Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy. Its first CAR therapy will be tested in patients with ovarian cancer. ... Mesothelin is expressed at elevated levels by a number of cancer types, including prostate and bile duct cancer, and  has

Latest news

More from news
Approximately 49 fully matching, plus 308 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Billy Connolly received the news of his diagnosis for dementia and prostate cancer on the same day:. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht, ”he

  • Deal Watch February 2017 Deal Watch February 2017

    In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological

  • Deal Watch August 2016 Deal Watch August 2016

    35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

  • Deal Watch May 2016 Deal Watch May 2016

    The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already ... 110. CSPC Pharmaceutical/ Watson [Allergan]. Licence.

More from intelligence
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 7 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics